Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?

Area of Science:

• Veterinary Oncology
• Immunomodulation
• Canine Cancer Research

Background:

• Canine haemangiosarcoma, particularly splenic, is an aggressive cancer with poor prognosis.
• Current treatment options for canine haemangiosarcoma have limited efficacy in improving long-term survival.
• Adjuvant therapies are crucial for managing micrometastatic disease and improving outcomes.

Purpose of the Study:

• To evaluate thalidomide as an adjuvant treatment for canine haemangiosarcoma.
• To determine the impact of thalidomide on the survival time of dogs with splenic haemangiosarcoma.
• To assess the safety and efficacy of thalidomide in this canine population.

Main Methods:

• A prospective study involving 15 dogs diagnosed with splenic haemangiosarcoma.
• Dogs underwent splenectomy followed by continuous thalidomide treatment.
• Tumor staging via CT scans and confirmation of cause of death through post-mortem examination.

Main Results:

• The median survival time for dogs receiving thalidomide was 172 days.
• 33% of dogs (5 out of 15) survived for over a year.
• Dogs with stage 2 disease showed significantly longer survival than stage 3 (303 vs. 40 days).

Conclusions:

• Thalidomide demonstrates potential as an effective adjuvant therapy for canine splenic haemangiosarcoma.
• The study suggests thalidomide may improve survival rates in affected dogs.
• Further investigation into thalidomide's role in canine cancer management is warranted.